Vraylar (cariprazine) is one of the least sedating atypical antipsychotics available. In clinical trials, sleepiness rates were only slightly higher than placebo, and researchers who analyzed the full range of second-generation antipsychotics classified Vraylar as “predominantly activating” rather than sedating. That said, some people do experience drowsiness, and the likelihood varies by dose and condition being treated.
How Sedating Vraylar Is in Clinical Trials
Across multiple clinical trials, the percentage of people reporting sleepiness on Vraylar was consistently low and often close to placebo rates. In six-week schizophrenia trials, 7% of Vraylar-treated patients reported somnolence compared to 6% on placebo. That’s a difference of just one percentage point. For bipolar mania, the gap was slightly wider: 8% on Vraylar versus 4% on placebo. In bipolar depression trials, the numbers were 6% to 7% on Vraylar versus 4% on placebo.
The one exception worth noting is an eight-week trial for major depressive disorder, where Vraylar was used alongside an antidepressant. In that study, sleepiness reached 10% to 11% of patients compared to 6% on placebo. That’s still modest by antipsychotic standards, but it’s the highest sedation rate seen with this medication in any trial.
How Vraylar Compares to Other Antipsychotics
When researchers compared the side effect profiles across all second-generation antipsychotics, Vraylar and lurasidone (Latuda) stood out as predominantly activating. That means their most common side effects lean toward restlessness and akathisia rather than drowsiness and fatigue. Olanzapine (Zyprexa), quetiapine (Seroquel), ziprasidone, asenapine, and iloperidone were all classified as predominantly sedating.
To put this in practical terms: quetiapine causes significant drowsiness in a large proportion of people who take it, which is why it’s sometimes used specifically as a sleep aid. Vraylar sits at the opposite end of the spectrum. If you’ve taken a more sedating antipsychotic before and are switching to Vraylar, you’re likely to notice a meaningful difference in daytime alertness.
Sedation Increases Slightly With Higher Doses
There is a dose-dependent pattern. In schizophrenia trials, sleepiness was reported by 5% of patients at 1.5 to 3 mg per day (identical to placebo), rising to 8% at 4.5 to 6 mg per day and 10% at the highest doses of 9 to 12 mg. The same trend appeared in bipolar mania trials, where somnolence went from 7% at 3 to 6 mg per day to 8% at 9 to 12 mg.
At the lower doses commonly used for bipolar depression and as an add-on for major depression (1.5 to 3 mg), sedation rates stay in the 5% to 7% range. Higher doses are more likely to cause some drowsiness, though even at the top of the dosing range, Vraylar remains far less sedating than medications like quetiapine or olanzapine.
Activation Is More Common Than Sedation
For most people taking Vraylar, the more relevant concern is actually the opposite of sedation. Akathisia, a feeling of inner restlessness or an inability to sit still, is one of the most frequently reported side effects. Some people also experience insomnia or agitation. This activating profile is part of why Vraylar is categorized differently from older atypical antipsychotics that tend to make people feel sluggish or mentally foggy.
If you’re wondering whether Vraylar will make you feel tired or wired, the data suggest “wired” is the more common experience, though neither happens to the majority of people taking it.
Timing Your Dose to Manage Drowsiness
Vraylar doesn’t have a required time of day for dosing. If you’re among the smaller group of people who do feel sleepy on it, taking your dose before bed can reduce daytime drowsiness. If you experience the more common activating effects like restlessness or difficulty sleeping, a morning dose may work better. Your experience in the first few weeks will guide the best timing.
One thing to keep in mind: cariprazine has an unusually long half-life compared to other antipsychotics. Its active form stays in your body for days, not hours. This means the sedation (or activation) you feel isn’t a sharp peak-and-valley tied to when you swallow the pill. Effects build gradually and remain relatively steady throughout the day regardless of dosing time, though some people still notice a difference with morning versus evening dosing.